Investor Relations
Apothify is a peptide education and commerce platform built around structured learning, side by side comparison, certificate of analysis transparency, batch level traceability, and a compliance first product strategy. We are preparing for a future round and are speaking with qualified investors, strategic partners, manufacturers, and distributors who are aligned with how we are building the category.
Positioning
Apothify brings together a structured peptide encyclopedia, a guided peptide finder, a side by side comparison tool, and a research product catalog. The library currently spans 110 peptides across 8 research areas. 54 are offered as research products with full COA and batch transparency. 56 are presented as encyclopedia entries only when regulatory considerations or compliance review status make commerce inappropriate.
Why Apothify
Every peptide page uses the same six section structure so a reader can scan, compare, and orient themselves without prior background. The library reads like a research reference, not a catalog.
Peptides flagged by regulators or held for internal compliance review never enter the cart pathway. They live as encyclopedia entries with no purchase option, no price display, and no checkout flow. This keeps the catalog defensible as the category evolves.
Every product page exposes the SKU, size, batch number, lab name, purity, certificate of analysis link, and warning level. The same data flows into order confirmations and tracking emails, so a customer never has to ask for it.
Market opportunity
Public interest in peptides has grown across multiple adjacent categories. The research, longevity, recovery, cosmetic, and metabolic spaces all touch peptide chemistry. At the same time, regulatory attention on this category has increased, which means buyers gravitate toward operators who frame products responsibly and exclude items that are not appropriate for sale.
Apothify is positioned in that gap. The platform offers serious educational depth, holds compliance as a product feature, and concentrates commerce on products that meet our internal standards. We believe the operators who clear the regulatory bar over time will absorb the category as it matures.
Platform advantages
Behind the surface, the platform runs on a serverless architecture with admin tooling for product editing, processor stability gates before publish, a banned phrase scanner across every editorial field, a full audit log, and order management. The technical foundation supports rapid catalog expansion in controlled batches without breaking compliance posture.
Compliance first product strategy
Apothify offers products for sale only when they pass our internal compliance review and are not flagged by regulators or otherwise restricted under our standards. Every SKU passes a ten item processor stability checklist before it is allowed to publish. That includes COA verification, batch traceability, copy review for medical claims, and confirmation of warning level and interaction notes.
Items that do not meet that bar are not removed from the site. They are presented as encyclopedia entries so the reader can still learn about them, with no cart, no checkout, no price, and no purchase pathway. The library remains comprehensive while the catalog stays clean.
Manufacturer and distributor alignment
Apothify works with manufacturers and distributors that already service practitioners, clinics, and advanced research customers in the peptide space. This gives the platform sourcing depth, COA continuity, and pricing structure that match the expectations of the existing market.
We are open to additional manufacturer and distributor relationships that share our compliance posture. Reach out via the contact below.
Future round
Apothify has completed an initial capital round and is preparing for a subsequent round. We are speaking with qualified investors and strategic partners who understand the category, are aligned with our compliance posture, and want to help expand the platform thoughtfully.
